Transmucosal Drug Delivery MarketPosted by Devanand on April 14th, 2021 Transmucosal drug delivery is a novel route of drug administration which includes buccal, nasal, vaginal, and urethral cavities as route of drug delivery. Technological advancements and growing focus on research and development to analyze new delivery systems for medication in human have cemented the method for transmucosal drug delivery market in the recent times. Transmucosal drug delivery system offers various advantages over other routes of drug administration, making it a highly lucrative market for the companies involved in its value chain. One of the primary advantages of transmucosal drug delivery is it allows drugs to dodge the body’s natural defense mechanism. Many drugs, when administered by other delivery routes, may become ineffective due to high gastric acidity or first pass metabolism. As mucosal cavity, such as, nasal, vaginal, urethral, etc. has a permeable membrane that has a rich supply of blood vessels in the lining, drugs administered through these routes can be directly absorbed into the circulatory system and delivered at the target sites. Rise in trend of home health care is anticipated to drive the growth of the global transmucosal drug delivery market during the forecast period. Moreover, rapidly rising incidence of chronic disorders, including gastrointestinal, respiratory, and autoimmune disorders is anticipated to propel the global transmucosal drug delivery market in the near future. Read Report Overview - https://www.transparencymarketresearch.com/transmucosal-drug-delivery-market.html The global transmucosal drug delivery market can be classified on the basis of indication, route of administration, and region. On the basis of indication, the market can be divided into pain management, addiction treatment, hormonal therapies, and others. Based on route of administration, the market can be segmented into buccal, nasal, vaginal, and urethral. In terms of region, the global transmucosal drug delivery market can be categorized into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global transmucosal drug delivery market, followed by Europe, owing to high adoption of advanced treatment approaches and high prevalence of various chronic and acute disorders in the region. Furthermore, the region is home to several key players which boosts the transmucosal drug deliver market in the region. Favorable reimbursement landscape, aggressive awareness programs, better diagnostic measures, and presence of advanced therapy brands make North America a highly promising market for transmucosal drug delivery. Major pharmaceutical companies in Europe, such as, Roche and Novartis have a diverse and multicultural skill-based research scientists and experienced managers adept at recognizing the market value of new methods. This has led to the adoption of superior practices in drug safety and development of new therapies in the region. Request Brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=53544 In Asia Pacific, the transmucosal drug delivery market is expected to grow at a significant rate due to the rapidly growing health care industry in major countries, such as, China, India, Japan, and Australia. Changing lifestyles and increasing urbanization in these countries have led to a gradual escalation in incidence of lifestyle diseases, such as, cancer, diabetes, and heart conditions. This has created multiple opportunities for the bio-pharmaceutical sector to expand, conduct research, and allocate substantial budget for the same. Moreover, the rapidly expanding pharmaceutical industry has attracted the focus of public and private organizations toward this market. Development of health care infrastructure, rise in population, boom in the biotechnology industry, and increase in the burden of diseases necessitating diagnostics are driving the growth of the transmucosal drug delivery market in Latin America. In addition, better distribution network and its proximity to the U.S. geographically are boosting the growth of the transmucosal drug delivery market in Latin America. Major players operating in the global transmucosal drug delivery market include Cephalon, Inc., 3M Company, Antares Pharma, Inc., Teva Pharmaceuticals, West Therapeutic Development, LLC, Mylan, Inc., and BioDelivery Sciences International, Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions. Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders. Like it? Share it! More by this author |